Company Overview of Putney, Inc.
Putney, Inc., a pet pharmaceutical company, develops and sells generic prescription medicines for pets. It provides veterinary-approved products, such as Enrofloxacin flavored tablets for use in dogs and cats for the management of diseases associated with bacteria susceptible to Enrofloxacin; Cefpodoxime Proxetil tablets to dogs for the treatment of skin infections (wounds and abscesses); Mupirocin ointment for the topical treatment of canine bacterial infections of the skin; Carprofen caplets to dogs for pain associated with canine osteoarthritis, and for controlling post-operative pain from certain surgeries; and Ketamine HCl for Injection C-III, a nonnarcotic nonbarbiturate agent for anes...
One Monument Square
Portland, ME 04101
Founded in 2006
Key Executives for Putney, Inc.
Founder, Chairman, Chief Executive Officer and President
Vice President of Finance and Controller
Senior Vice President of Regulatory Policy and Counsel
Vice President of Human Resources
Compensation as of Fiscal Year 2015.
Putney, Inc. Key Developments
Putney, Inc. Launches Tiletamine-Zolazepam, First-To-Market Generic of Telazol
Jun 17 15
Putney, Inc. announced that its Tiletamine-Zolazepam (tiletamine HCl and zolazepam HCl) injectable, the only FDA-approved generic of Zoetis’ Telazol, is now commercially available. Veterinarians can purchase the drug through one of Putney’s network of regional distributors or directly from Putney. National veterinary distributors are prevented from carrying Putney’s Tiletamine-Zolazepam by “exclusive dealing agreements”, so-called in the recent FTC report entitled “Competition in the Pet Medications Industry.
Putney, Inc. Launches Putney Carprofen Chewable Tablets
Dec 18 14
Putney, Inc. announced that it is launching Putney Carprofen Chewable Tablets, its FDA approved generic of Zoetis’ popular Rimadyl® Chewable Tablets. With this product approval, the company’s fourth in less than three months, Putney is the company with FDA approved generics of all three dosage forms of carprofen products – Putney Carprofen Chewable Tablets, Putney Carprofen Sterile Injectable Solution, and Putney Carprofen Caplets. Putney’s other recent FDA approvals include Putney Dexmedetomidine HCl, a first-to-market generic of Dexdomitor® and the company’s third approval of a first-to-market generic in less than two years. Putney expects to penetrate and expand the $70 million carprofen chewable tablet market rapidly as veterinarians opt to save approximately 30% on Putney’s bioequivalent product (compared to Rimadyl® Chewable Tablets current list price).
Putney, Inc. Hires Catherine Conaty as Vice President of Finance & Controller
Dec 10 14
Putney, Inc. hired Catherine Conaty as Vice President of Finance & Controller, reporting to the company's CFO, William McKee. Conaty joins the company’s senior management team to lead the finance department and implement efficient systems and processes to support Putney’s commercial growth in 2015 and beyond. In addition to her financial responsibilities, she will oversee the company’s IT department and the continuing implementation of a cloud-based ERP system, the first phase of which has already been successfully completed across the company’s finance department. Conaty has over thirty years of financial management experience, most recently with a series of early stage technology and pharmaceutical companies where she was instrumental in building the financial systems and reporting infrastructure to support high growth following new product launches.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|